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Abstract
Background: Alzheimer’s disease (AD) brain shows an ongoing inflammatory condition and non-steroidal anti-
inflammatories diminish the risk of suffering the neurologic disease. Cannabinoids are neuroprotective and anti-
inflammatory agents with therapeutic potential.
Methods: We have studied the effects of prolonged oral administration of transgenic amyloid precursor protein
(APP) mice with two pharmacologically different cannabinoids (WIN 55,212-2 and JWH-133, 0.2 mg/kg/day in the
drinking water during 4 months) on inflammatory and cognitive parameters, and on 18F-fluoro-deoxyglucose
(18FDG) uptake by positron emission tomography (PET).
Results: Novel object recognition was significantly reduced in 11 month old Tg APP mice and 4 month
administration of JWH was able to normalize this cognitive deficit, although WIN was ineffective. Wild type mice
cognitive performance was unaltered by cannabinoid administration. Tg APP mice showed decreased 18FDG
uptake in hippocampus and cortical regions, which was counteracted by oral JWH treatment. Hippocampal GFAP
immunoreactivity and cortical protein expression was unaffected by genotype or treatment. In contrast, the density
of Iba1 positive microglia was increased in Tg APP mice, and normalized following JWH chronic treatment. Both
cannabinoids were effective at reducing the enhancement of COX-2 protein levels and TNF-a mRNA expression
found in the AD model. Increased cortical b-amyloid (Ab) levels were significantly reduced in the mouse model by
both cannabinoids. Noteworthy both cannabinoids enhanced Ab transport across choroid plexus cells in vitro.
Conclusions: In summary we have shown that chronically administered cannabinoid showed marked beneficial
effects concomitant with inflammation reduction and increased Ab clearance.
Keywords: Alzheimer’s disease, β-amyloid peptide, cannabinoids, glial activation, interleukin 6, anti-inflammatories,
tumor necrosis factor-α
Background
Alzheimer’s disease (AD) is the major cause of demen-
tia. The cognitive impairment is associated with the
degeneration of particular subsets of neurons in regions
involved in learning and memory processes. In addition
another invariant feature of AD is neuroinflammation,
considered a consequence of glial activation and
reflected as astrogliosis and microglial activation, in par-
ticular around senile plaques, one of the pathological
hallmarks of the disease, along neurofibrillary tangles.
Indeed, lots of inflammatory parameters are found in
AD brains [1,2]. Once initiated the inflammatory pro-
cess it may contribute independently to neural dysfunc-
tion and cell death, establishing a self-perpetuating
vicious cycle by which inflammation induces further
neurodegeneration. The recognition of inflammation as
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an important component in the disease led to the dis-
covery that prolonged treatment with non-steroidal anti-
inflammatories (NSAIDS) had beneficial effects for AD.
Indeed, several prospective works have shown that this
kind of treatment markedly reduced the risk of suffering
the neurologic condition, delayed its onset, ameliorated
the symptomatic severity and slowed cognitive decline
[3-5]. However their administration to already demented
patients may be ineffective, suggesting the importance of
early administration or, alternatively, the existence of
additional targets of NSAIDs, besides cycloxygenase
inhibition. Nevertheless, other compounds with anti-
inflammatory activity may be disease modifying drugs,
which may delay onset or slow its progression, in con-
trast with the present AD palliative treatment.
Cannabinoids, whether plant derived, synthetic or endo-
cannabinoids, interact with two well characterized canna-
binoid receptors, CB1 and CB2 [6,7]. In addition, some
cannabinoids may interact with other receptors, such as
the TRPV1 receptor or the orphan receptor GPR55 [8,9].
The CB1 receptor is widely distributed, with a particularly
high expression in brain, which contrasts with the limited
expression of the CB2 receptor, which is characteristic of
immune organs and cells [10]. In fact, while CB1 receptors
are expressed by all types of cells in the brain (neurons
and glial cells), CB2 are mainly localized in microglial cells
[6,9-11], the resident immune cell of the brain.
We and others have proposed cannabinoids as preven-
tive treatment for AD [12-14], based on their neuropro-
tective [15,16] and anti-inflammatory effects [11,17,18].
Indeed, cannabinoids are able to decrease the release of
cytokines and nitric oxide in cultured microglial cells
induced by lipopolysacharide [19,20] and Ab addition
[12,21]. In several in vitro studies cannabidiol (CBD), the
major non-psychotropic constituent of cannabis, has
shown to be neuroprotective against b-amyloid (Ab)
addition to cultured cells. This action was a consequence
of reduction of oxidative stress and blockade of apoptosis
[22], tau-phosphorylation inhibition through the Wnt/b-
catenin pathway [23] and decreased iNOS expression and
nitrite generation [24]. In vivo experiments have shown
that several cannabinoids were effective at preventing
Alzheimer’s disease related changes. In a previous work
we have reported that synthetic cannabinoids, such as
WIN55,212-2 and JWH-133, prevented the cognitive
impairment, glial activation and neuronal marker loss in
b-amyloid injected rats [12]. Enhancement of endocanna-
binoid levels by subchronic uptake inhibition reversed
the increase in inflammatory parameters, such as COX-2,
TNF-a and IL-1, in Ab-injected mice, although cognitive
impairment was only prevented in early treated mice
[25]. Further, we have recently reported that CBD and
WIN55,212-2 (WIN) inhibited both glial activation and
cognitive deficits, as judged in the water maze test, and
by a mechanism involving decreasing microglial activa-
tion, as shown in cultured microglial cells [20].
So far the possible effects of cannabinoids have not
been studied in a genetic AD model, which mimics the
amyloidosis and neuroinflammation [26,27] that occurs
in the neurologic condition, in the absence of overt neu-
rodegeneration [28]. Therefore in this work we have
addressed the question whether cannabinoid agonists
would ameliorate the cognitive deficits, neuroinflamma-
tion and altered Ab levels in this AD model. To that end
we have used WIN 55,212-2 (WIN), a mixed CB1/CB2
agonist [6] and JWH-133 (JWH) as selective CB2 agonist
[29]. The CB2 selective agonist is devoid of psychoactiv-
ity, an advantage for its clinical endorsement, however
we reasoned that a low dose of WIN may be free of psy-
choactive effects as well. The drugs were administered in
drinking water [30] for a prolonged period, 4 months, to
mimic a possible clinical setting. Given that cannabinoid
treatment may be preventive, but not curative, adminis-
tration of drugs was started at 7 months of age, when no
cognitive dysfunction or plaque deposition exists, and it
was prolonged for 4 months (eg until 11 months of age).
We report here that such a treatment ameliorates cogni-
tive performance, decreases neuroinflammation and Ab
levels, likely by increasing its transport to the periphery.
Results
Effect of cannabinoid oral treatment on cognitive
impairment and glucose uptake by PET
In a previous work we assessed the effects of cannabi-
noids following intraventricular administration concomi-
tant to Ab injection for 7 days to rats [12]. This type of
administration is not feasible in the Clinic, and is
restricted to very few disease conditions. Other authors
have used oral administration of 0.1 mg/kg/day tetra-
hydrocannabinol (THC) effectively [30]. Therefore, in
this work we have chosen to administer cannabinoids in
the drinking water to investigate their effects in the
genetic model of AD. Given that we aimed a preventive
treatment, it was initiated at 7 months of age when they
do not exhibit Ab deposition in plaques [28].
First we examined whether continuous oral treatment
with a low dose (0.2 mg/kg/day for 4 months) of cannabi-
noids was able to rescue the cognitive impairment of Tg
APP eleven months old mice in the novel object recogni-
tion test. Exploration activity was monitored during the
training trial and all the animals displayed similar atten-
tion to the two identical objects. Wild type mice treated
with vehicle were able to discriminate between the famil-
iar object (Figure 1) and a novel object, exploring the lat-
ter for a longer time. WIN and JWH did not affect this
behavior in wild type mice, even after prolonged treat-
ment. As expected Tg APP mice did not distinguish both
objects, showing cognitive impairment. In contrast Tg
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APP mice treated with the CB2 selective cannabinoid
JWH spent more time exploring the novel object,
although WIN was ineffective at that respect.
18FDG uptake is significantly decreased in areas
involved in learning and memory both in AD patients
and in subjects showing mild cognitive impairment [31].
Moreover it is considered to be an early marker of the
neurologic disease. Prolonged WIN treatment reduced
the uptake in wild type mice (Figure 2 B, C, D), while
JWH was without effect. As expected 12 month Tg APP
vehicle treated mice had reduced 18FDG uptake (25-30%
depending on the region of interest; Figure 2 A, B, C, D).
JWH continuous administration fully reversed the reduc-
tion in glucose uptake in Tg APP mice (Figure 2 A, B, C,
D), which was slightly higher than that of wild type mice
(approximately 15%), while WIN was ineffective on that
respect. Therefore JWH, the CB2 selective agonist, was
capable of improving cognitive impairment and of rever-
sing the reduction in 18FDG uptake in cortical areas and
hippocampus of Tg APP.
Cannabinoids reduce microglial activation and
inflammatory parameters in Tg APP mice cerebral cortex
Neuroinflammation is reflected in AD and its transgenic
models brain as astrogliosis and microglial activation,
particularly surrounding senile plaques [26,28]. GFAP
immunohistochemistry showed similar staining patterns
in hippocampus in the different groups studied (Figure
3 A and 3B), irrespective of the genotype or the treat-
ment received. Similarly GFAP protein levels, as
assessed by Western blotting, were maintained across
the different groups (Figure 3 C and 3D). Microglial cell
staining and density was assessed by using ionized Ca2
+-binding adaptor molecule-1 (Iba-1) antibody. The anti-
body labeled resting microglial cells in wild type mice,
characterized by the fine tortuous branching, which was
unaffected by either of the cannabinoids used in the oral
chronic treatment (Figure 4, A). Tg APP vehicle treated
mice showed an increase (53%) in Iba-1 positive micro-
glial cells compared with wild type mice (Figure 4, A
and 4B). While continuous WIN treatment did not alter
this increased density, the CB2 selective agonist JWH
decreased cell density so that cell number accounted
83% of that of wild type mice (Figure 4 B). These results
indicate that at this age Tg APP mice do not show
astrogliosis, but they had microglial activation, which
was effectively counteracted by JWH oral treatment.
Recent works have shown increased CB2 microglial
expression following a lesion or in a neurodegeneration
context [32], including AD brain [13,33]. We also
addressed this issue by means of double immuno-fluores-
cence. We revealed CB2 expression in Iba-1 microglial
cells (additional file 1 A1-3) in quinolinic acid injected
striatum (additional file 2) and not in the contralateral
striatum (additional file 1, B1-3), as expected. However
there was no evident CB2 staining in any region exam-
ined of Tg APP mice (additional file 1, C1-3). Regarding
CB2 protein expression Tg APP mice had similar levels
compared to wild type mice which also received vehicle
(Figure 5 A and 5B). JWH administration, but not WIN,
to wild type mice reduced (45%) CB2 protein levels (Fig-
ure 5, B). Both WIN and JWH significantly decreased
CB2 protein (Figure 5, B) in the AD model, which
attained very low levels (around a 75%-80% reduction).
We used Western analysis or qRT-PCR to assess possi-
ble changes in inflammatory parameters in cerebral cor-
tex (Figure 5). JWH, but not WIN, decreased COX-2
expression in wild type mice (Figure 5 C and 5D). This
parameter was markedly increased a 49% in Tg APP
mice (Figure 5 D). Noteworthy, both cannabinoids effec-
tively reversed COX-2 protein enhancement, reaching
even lower levels than in wild type mice (40% and 60%
respectively vs. wild type vehicle treated mice).
Different cytokines have been shown to be increased in
AD brain and in its genetic model. IL-6 mRNA expres-
sion was similar across the different groups (Figure 5, E).
As expected cortical TNF-a mRNA expression was dra-
matically increased (around 6 fold vs wild type vehicle
treated mice; Figure 5 F). The cannabinoid agonists used
Figure 1 JWH oral administration rescued the cognitive
impairment of TgAPP. Cannabinoid agonists did not alter the
discrimination of the novel object (NO) compared to the familar
one (A) of wt mice. Tg APP failed to distinguish the NO, like those
treated with WIN, but JWH treatment restored normal
discrimination. Animals were treated with vehicle or cannabinoids
(0.2 mg/kg) in the drinking water for 4 months, starting at 7 months
of age. Time spent exploring either objects was expressed as
percentage of the total exploration time. Results are mean ± SEM
(5-7 mice/group). *p < 0.05 vs familiar object (ANOVA followed by
Student’s t test).
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Figure 2 JWH oral administration rescued the decreased 18F-DG uptake in TgAPP assessed by PET. A: representative images [MR, 18F-DG
uptake and merged] in hippocampus of wild type (Wt) and Tg APP vehicle treated mice. Continuous oral treatment of wild type mice with WIN
decreased uptake in all regions studied (B: hippocampus; C: Frontal cortex; D: Temporo-parietal cortex). Tg APP showed decreased uptake which
was normalized by JWH oral treatment (A-D). Animals were treated with vehicle or cannabinoids (0.2 mg/kg) in the drinking water for 4 months,
starting at 7 months of age. Results are mean ± SEM (n = 4 mice/group) of the ratio of average radiactivity in a given region of interest (ROI) by
the radiactivity in cerebellum (Cb) expressed as percentage. *p < 0.05, ** p < 0.01 vs vehicle treated mice; #p < 0.05 vs wild type-vehicle mice
(ANOVA followed by Student’s t test).
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in this study prevented this increase, although this cyto-
kine expression continued to be higher than that of wild
type mice (Figure 5, F).
Taken together these results demonstrate that contin-
uous cannabinoid administration has anti-inflammatory
activity given that different mediators were effectively
counteracted in Tg APP.
Cannabinoids oral administration decreases b-amyloid
levels and increases its transport through choroid plexus
monolayers
The Tg APP model parallels the amyloidosis of the neu-
rologic condition. Eleven month old Tg APP mice have
no detectable insoluble (formic acid extracted) Ab levels
by ELISA. As expected no soluble human transgenic Ab
levels were detected in wild type mice, while Tg APP
mice had high levels of Ab1-40 (Figure 6, A) and detect-
able levels of the more amyloidogenic Ab1-42 fragment
(Figure 6, B). JWH decreased by 27% the levels of Ab1-40,
and a 30% similar reduction in Ab1-42 was found follow-
ing the administration of either WIN or JWH (Figure 6,
A and 6B).
To determine the mechanism by which both cannabi-
noids reduce Ab levels first we examined the effect of both
compounds on Ab release from cultured APP/PS1 glioma
cells. There was no difference in the presence or the
absence of drugs (data not shown) suggesting that neither
the release nor the synthesis of Ab was altered. Next we
Figure 3 Cannabinoid oral administration did not alter GFAP immunostaining or protein expression. GFAP hippocampal immunostaining
(IR) or cerebral cortical protein expression was similar in all groups, irrespective of genotype or treatment. A: representative IR in hippocampus from
wild type and Tg APP mice treated with vehicle or cannabinoids. The area assessed is shown (5 hippocampal areas) B: Optical density (OD) was
measured by densitometry. C: representative GFAP Western blot (WB) and D: optical density (OD) in cortical samples. Animals were treated with
vehicle or cannabinoids (0.2 mg/kg) in the drinking water for 4 months, starting at 7 months of age. Results are mean ± SEM (n = 6-7 mice/group).
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wondered whether the cannabinoids would reduce Ab
levels by enhancing its clearance, a therapeutic strategy
intensively studied for AD treatment. Therefore we
assessed Ab transport across choroid plexus monolayers
in vitro. Since there are contradictory reports on the pre-
sence of CB1 receptors in choroid plexus [34,35] first we
performed stainings with CB1 and CB2 antibodies. We
revealed the presence of both receptors in rat choroid
plexus (Figure 6, C). Then we examined the possible time
course of the transport of Ab1-40 (5 μg/ml) added to the
upper compartment, by measuring the amount of peptide
in the lower compartment by Western blotting at different
time points (Figure 6 D). In the absence of any drug the
peptide was recovered at 12 h, and at longer times (24 and
48 h), after its addition to the upper compartment. How-
ever, the transport was much quicker in the presence of
WIN or JWH (200 nM) and Ab was mainly transported at
shorter times (1-3 h; Figure 6 D). To quantify this trans-
port we took advantage of ELISA assays and assessed pep-
tide levels at 1 and 3 h after the addition of Ab to the cell
cultures (Figure 6 E). WIN and JWH promoted the same
peptide transport both at 1 and 3 h, while almost no
detectable Ab crossed the choroid plexus cell monolayer
in their absence (Figure 6 E). In summary, prolonged oral
administration of cannabinoids effectively reduced Ab
levels in Tg APP brain, likely due to increased peptide
clearance through the blood- or the CSF-barrier.
Effect of prolonged oral treatment with cannabinoids on
GSK3-b levels
AD is characterized by the existence of increased tau phos-
phorylation, mainly by the action of GSK3-b, which is
deregulated. We assessed by Western blotting total and
pSer9-GSK3-b (inactive form) levels in cerebral cortex,
from Wt and Tg APP mice following the different treat-
ments. Cannabinoid agonist treatment did not change p-
Ser9 GSK3-b protein levels in wild type mice. In contrast,
there was a reduction (around 40%) in p-GSK3-b in the
AD model which was normalized by WIN administration,
but not JWH (28% decrease vs wild type vehicle treated
mice). Total GSK3-b protein levels remained largely
unchanged. Similarly no changes in the levels of either p-
Ser21 GSK3-a or total GSK3-a protein levels were
observed (Figure 7). Therefore, the pathological pSer9-
GSK3-b activity was normalized by the CB1/CB2 mixed
agonist WIN.
Discussion
In this work we describe several beneficial effects of the
prolonged oral treatment with two cannabinoid agonists
with different pharmacological profiles. Both cannabi-
noids were effective at decreasing the inflammatory
parameters and Ab levels. However, it was the CB2
selective agonist JWH that was able to prevent cognitive
deficits and glucose metabolism reduction.
Our results differ from a recent work [36] reporting
variable effects on water maze performance and fear
conditioning, no changes in Ab levels or plaque burden
following subchronic treatment with the CB1/CB2 mixed
agonist HU-210. Methodological differences may
account for the results, since they used male and female
double APP23/PS1 transgenic mice, at 4 (young) or 6-9
weeks of age, and a very low dose of the cannabinoid
agonist (10 or 50 μg/kg) injected twice daily [14].
CB1 activation induces psychoactive effects. In fact
mixed CB1/CB2 and CB1 selective agonists after acute
Figure 4 Microglial cell density was increased in Tg APP and decreased by continuous JWH oral treatment. A: representative Iba-1
immunostaining in cerebral cortex following the different treatments. B: microglial cortical cell density. Animals were treated with vehicle or
cannabinoids (0.2 mg/kg) in the drinking water for 4 months, starting at 7 months of age. Results are mean ± SEM (n = 6-7 mice/group). #p <
0.05 vs wild type vehicle treated mice; * p < 0.05 vs Tg APP vehicle treated mice (ANOVA followed by Student’s t test).
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administration decrease motor activity and impair learn-
ing and memory [37-39], although at higher doses than
the one we used in this study (0.2 mg/kg/day). However,
chronic administration of those drugs induces tolerance
to their acute effects in different behavioural tests
[40,41]. Therefore, the fact that WIN did not affect learn-
ing in the novel object recognition test in wild type mice
might suggest tolerance after prolonged administration.
Similarly WIN was without effect on recognition memory
of Tg APP mice. In contrast, CB2 selective agonists, such
as JWH, are devoid of psychoactivity after acute adminis-
tration and does not alter motor activity [[42], Martín-
Moreno et al., in preparation] after systemic administra-
tion or object recognition memory following its intrahip-
pocampal injection [43]. After prolonged administration
to wild type mice JWH neither altered learning nor mem-
ory in the present work. Interestingly this compound
effectively counteracted the cognitive impairment of Tg
APP mice.
The brain is the organ with the highest glucose con-
sumption, which is believed to be coupled to neural
activity. The reduction in brain glucose uptake has been
repeatedly demonstrated in AD patients [31,44], in parti-
cular in regions involved in memory, and it is highly
Figure 5 Cannabinoid oral treatment decreased inflammatory parameters of Tg APP mice. A, B: Cannabinoids decreased CB2 protein
levels by Western blotting in Tg APP. C, D: Cannabinoids counteracted the increase in COX-2 protein levels by Western blotting. E: IL6 mRNA
expression (qRT-PCR) was similar in all groups studied. F: Cannabinoids blocked the increased TNF-a mRNA expression (qRT-PCR) in Tg APP.
Animals were treated with vehicle or cannabinoids (0.2 mg/kg) in the drinking water for 4 months, starting at 7 months of age. Results are mean
± SEM (n = 6-7 mice/group) *p < 0.05, ** p < 0.01 vs vehicle treated mice; #p < 0.05 vs wild type mice vehicle treated mice (ANOVA followed
by Student’s t test).
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correlated with cognitive deficits. Prolonged oral WIN
administration reduced glucose uptake, as measured by
PET 18F-DG, in wild type mice in cortical regions and
hippocampus. This result may be deleterious, in spite of
the observation of no memory impairment in the cogni-
tive test selected. In fact, previous autoradiographic work
has reported either normal 3H-DG uptake in hippocam-
pus or a decrease, depending on the dose of WIN [45]
acutely administered. Decreased 18F-DG uptake in Tg
APP in the present work is in essential agreement with
previous reports, either by autoradiographic techniques
[46] or PET [47]. Notably JWH administration for 4
months did not alter glucose uptake in wild type mice,
while it completely abrogated the reduction observed in
Tg APP. Brain activity in general, and cognition in parti-
cular rely on glucose metabolism [47], therefore the
effects of the CB2 agonist on both glucose utilization and
recognition memory are of therapeutic interest.
Inflammation has several drawbacks including learning
and memory impairment [48], in particular during ageing
Figure 6 Cannabinoids decreased Ab levels of Tg APP mice and increased transport through choroid plexus cell monolayer. A: Both
cannabinoids significantly decreased Ab1-42 cortical levels. B: JWH decreased Ab1-40 cortical levels in Tg APP mice. Animals were treated with
vehicle or cannabinoids (0.2 mg/kg) in the drinking water for 4 months, starting at 7 months of age. Results are mean ± SEM (n = 6-7 mice/
group) C: rat choroid plexus express both CB1 and CB2 receptors. D: time-course of Ab1-40 transport through choroid plexus cells. Both
cannabinoids (200 nM) reduced the transport time compared to untreated cultures (representative Western blot). E: Cannabinoids enhanced Ab1-
40 transport through choroid plexus cells at 1 and 3 h after addition vs untreated control cultures (mean ± SEM, n = 4). E: *p < 0.05, *** p < 0.01
vs vehicle treated mice or cultures (Student’s t test).
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Figure 7 WIN oral treatment counteracted decreased phospho-Ser9 GSK3b in cerebral cortex of Tg APP mice. A: representative Western
blot of p-Ser9 GSK3b. B: optical density (OD). C: total-GSK3b. D: optical density (OD). E: representative Western blot of p-Ser21 GSK3a. F: optical
density (OD). G: total-GSK3a in cerebral cortex. H: optical density (OD). Wild type (Wt) and Tg APP mice were treated with vehicle or cannabinoids
(0.2 mg/kg) in the drinking water for 4 months, starting at 7 months of age. Results are mean ± SEM (n = 6-7 mice/group) *p < 0.05 vs wt-veh
mice, # p < 0.05 vs Tg APP-vehicle treated mice; #p < 0.05 vs wild type vehicle treated mice (ANOVA followed by Student’s t test).
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[49,50]. The compounds under study behaved as anti-
inflammatory agents, in agreement with previous reports
[11,12,20,25,49-51]. Microglial activation, but not astro-
gliosis, was observed in 11 month old Tg APP mice. Pre-
vious works have shown prominent reactive astrogliosis
and increased GFAP expression in transgenic mice, that
appears to be age-dependent and related with disease
progression [26,28,52], albeit being restricted to plaques.
The lack of astrogliosis and changes in GFAP expression
may be explained by the absence of plaques in the mice
model at this age. This result is in agreement with the
detection of GFAP mRNA, as assessed by non-radioactive
in situ hybridization, in reactive astrocytes in close proxi-
mity with Ab plaques at 14 months of age, but not
before, when plaques were absent [53]. Indeed we found
no plaques with glial associated cells, although there was
a significant enhancement in microglial cell density in Tg
APP mice. Continuous JWH treatment for 4 months nor-
malized this parameter, but WIN was ineffective. In dif-
ferent contexts (eg lesions) both astrocytes and microglia
could be engaged in inflammation. However in light of
those results we can ascribe the increase in inflammatory
mediators to microglial activation, given that there was
no overt astrogliosis. COX-2 protein levels and TNF-a
mRNA expression is increased in AD and its transgenic
model [54,55]. Both cannabinoids significantly decreased
COX-2 and TNF-a, as expected, since both compounds
share CB2 receptor activation, as shown by the down-reg-
ulation of its expression in Tg APP mice. It should be
noted that although CB2 receptors could be expressed by
some neurons [56] they are mainly expressed by micro-
glial cells [6,9-11], and are involved in the modulation of
several inflammatory mediators [12,19-21,25]. We did
expect an increase in CB2 receptor expression in the
transgenic model given that Ab addition to microglial
cultures enhance it [21]. However, in Tg APP mice we
did not observe CB2 co-localization with Iba-1, which
contrasts with the microglial co-expression in AD brain
[13,33]. We neither found an increase by Western blot-
ting, in agreement with our previous results in AD
patients or Ab-injected rats [12]. This supports the
notion that at this age there is an ongoing glial activation
of low magnitude in Tg APP and that cannabinoids
down-modulate this response.
Ab removal is considered a therapeutic strategy in
AD, promoted either by vaccination [57,58] or by
enhancing its clearance towards the periphery [59,60].
One of the most interesting findings of the present
work is the Ab lowering ability of both cannabinoids,
which we report for the first time. Prolonged oral JWH
treatment decreased Ab1-40 levels in brain and both can-
nabinoids decreased the more amyloidogenic fragment,
Ab1-42. Given that the drugs did not alter Ab release we
speculated that APP cleavage was not altered, and
therefore studied whether cannabinoids changed the
peptide transport in vitro. Rat choroid plexus expressed
CB1, in agreement with [34], and also CB2 receptor pro-
tein, making feasible their activation by the drugs under
study. Cannabinoids favored Ab transport, that was
mainly observed at shorter times (1-3 h) compared to
control experiments. This interesting effect merits
further study.
At variance with those effects oral treatment with WIN,
but not JWH, normalized the levels of GSK3-b in Tg
APP mice. Neurofibrillary tangles (NFTs), resulting from
an abnormal phosphorylation of microtubule-associated
tau proteins, represent a key pathological hallmark of
Alzheimer’s brain. GSK3-b is the kinase mainly responsi-
ble for tau hyperphosphorylation, therefore inhibiting its
activity is considered of therapeutic interest. The effect of
WIN after prolonged oral administration is in accordance
with reports showing a CB1 dependent increase in GSK3-
b phosphorylation in cultured cells [61], in brain after
acute cannabinoid agonist administration [62], and with
a reduction in tau phosphorylation [23]. Neurofibrillary
tangles are intraneuronal elements and neurons are in
general devoid of CB2 receptors. Therefore the effects of
WIN on GSK3-b, which were not mimicked by the CB2
selective agonist JWH, might be explained by its interac-
tion with CB1 receptors in neurons.
Given that our previous work had shown that cannabi-
noids were preventive against the Ab effects, both in
vitro and in vivo [12,20] we decided to start the continu-
ous oral treatment at 7 months of age. At this time Tg
APP mice do not have plaques and show normal learning
and memory compared to wild type mice. Nevertheless,
the treatment ended at 11 months of age when Tg APP
begin to show memory disruption. According to our
results the prolonged drug treatment decreased micro-
glial activation of Tg APP mice along several inflamma-
tory mediators, which were increased. However, ageing
alters microglial responsiveness (eg to Ab production
and deposition), which is highly dynamic and context
dependent [63]. Therefore a potential caveat of our
results is that they may not be applicable to aged patho-
logical microglia as occurs in severe AD. However, a pre-
ventive treatment at very early stages of the disease may
be feasible and beneficial as has been shown with the
anti-inflammatory trifusal, both in amnestic mild cogni-
tively impaired patients [64] and in Tg APP mice [65].
Over the last decade important findings on the involve-
ment of the endocannabinoid system in AD has been
gathered. Indeed, in AD brain there is increased expres-
sion of CB2 receptors in microglia and of fatty acid amide
hydrolase, the enzyme responsible for anandamide degra-
dation, in astrocytes around plaques [13]. However CB1
localization is markedly altered and its protein expression
and functionality diminished [12]. Furthermore, molecular
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rearrangements in different endocannabinoid system ele-
ments suggest that 2-AG signaling is increased, possibly
contributing to synaptic failure in AD [66], while ananda-
mide levels are decreased and are inversely correlated with
Ab levels [67]. Interestingly, the CB2 receptor expression
has been reported to be increased both in the brain of AD
patients [68] and in peripheral blood, where a significant
correlation was found with the dementia score [69].
Finally, a CB2 PET radiotracer is accumulated in brains
showing neuroinflammation (eg LPS injected and Tg
APP/PS1 mice; [70]). These latter results suggest the
importance of CB2 receptor as a biomarker of the neurolo-
gic disease, but also as a therapeutic target. CB2 receptor
increased expression in AD appears to be a consequence
of microglia activation, but more importantly they render
microglia susceptible to cannabinoid modulation, decreas-
ing the generation cytotoxic molecules and inhibiting
microglial activation, while promoting its migratory activ-
ity [10,11,20].
Conclusions
In summary, cannabinoid agonists, in particular CB2
selective agonists, interfere with several interconnected
events of importance in the pathophysiology of AD.
These compounds by directly interacting with cannabi-
noid receptors, in particular CB2, decrease microglial
activation thereby reducing inflammation and its conse-
quences (eg cognitive deficits). At the same time they
may indirectly have beneficial effects on microglial acti-
vation (eg decrease cytokine release) by lowering brain
Ab levels.
Methods
Animals and treatments
Tg APP transgenic mice were obtained via heterozygous
breeding of mice expressing the 695 aa long isoform of
the human APP containing a double mutation Lys 670-
Asn, Met 671-Leu [52] (swedish mutation) under tran-
scriptional control of the hamster prion promoter on a
C57/BL6 breeding background. Male Tg APP and wild
type littermates, used as controls, were 7 months age at
the beginning of the experiments. Mice were group-
housed (4-5 animals per cage) with a 12:12 h light/dark
cycle and with ad libitum access to food and water. All of
the experiments were performed according to ethical reg-
ulations on the use and welfare of experimental animals
of the European Union and the Spanish Ministry of Agri-
culture, and the procedures were approved by the
bioethical committee of the CSIC.
WIN 55,212-2 (WIN) and JWH-133 (JWH) were
administered in the drinking water at a dose of 0.2 mg/
kg/day using ethanol (0.1%) as vehicle. The amount of
water drank by the animals was assessed every other day
and the treatment was adjusted to their weight. There
was no difference in the body weight or the ingested
water between groups, all along the experiment, discard-
ing a possible reinforcing effect of cannabinoids.
Animals were sacrificed by cervical dislocation fol-
lowed by decapitation at 11 months of age. The brain
was saggitally divided. One hemisphere was rapidly dis-
sected on a cold plate, frozen on dry ice and stored at
-80°C until assayed. The other hemisphere was immer-
sion fixed in PF 4% in PB 0.1 M for 24 h, cryoprotected
in sucrose 15% (24 h) and 30% (24 h) in PB, snap frozen
in hexane (-60°C) and stored at -20°C until cut with a
sliding microtome.
Novel object recognition test
The arena measured 40 × 40 cm, surrounded by 30-cm-
high perimeter black walls, that was located in an isolated
room that was novel to the animals. The floor of the arena
was covered with used sawdust. The arena was monitored
by a video-camera located above the arena. The procedure
consisted in three visits to the arena in subsequent days.
The first day mice were placed into the empty arena for
15 min (habituation). The second day they were allowed
to explore two identical objects during two 10 min trials 5
min apart (training). On the third day (test), one of the
objects was changed by a novel one, with different shape
and color, and the mice explored the arena for 10 min.
Data collection was carried out by the Ethovision software
(Noldus, The Netherlands) and exploring was defined as
“directing the nose at a distance equal to or less than 3 cm
from the object or touching it with the nose”. The time
spent exploring the familiar object and the new object was
expressed as a percentage. Objects were cleaned before
every exposure with acetic acid 0.1% to prevent any olfac-
tory clues. Experiments were performed at the same time
of the day (9.00-14.00 h).
18Fdeoxyglucose (18FDG) Positron Emission
Tomography (PET)
Fasted mice were anesthetized with isofluorane (2%) and
injected (ip) with 18FDG (11,1 MBq or 300 μCi/200 μl sal-
ine, PET Technologic Institute, Madrid). Thirty min later
18FDG uptake images of each mouse were acquired for 30
min by PET imaging (Albira PET, 8 detectors, Gem-Ima-
ging, Spain; [71]). The regions of interest were previously
delineated in magnetic resonance (MR) T2-weighted
images (Bruker Biospin, Germany) of each animal. Quanti-
fication of the metabolic activity was performed by co-
registering the PET images of the brains to their own MR
image as described by [72]. In our case, the field of view
(FOV) of the PET scanner is 80 × 80 × 40 mm and the
number of pixels of the reconstructed tomographic image
is 160 × 160 × 80 pixels, being the voxel size 0.5 mm3.
Co-registration of the PET image to the MRI, leads to a
reduction of the pixel size to 0.2 mm3, given the trilinear
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interpolation done by the PMOD software (PMOD Tech-
nologies, version 2.9, Switzerland). The 18FDG uptake of
the different brain areas were normalized to the 18FDG
uptake in the cerebellum (considered as reference region).
Immunohistochemistry and image analysis
Immunostaining was performed on floating sections (35
μm) as described previously [12]. In brief, following several
washes with PBS, the endogenous peroxidase was blocked
(3% hydrogen peroxide in methanol), washed again, and
incubated for 90 min in PB containing 0.2% Triton × 100
and 10% normal goat serum. Sections were incubated with
the different antibodies in PB containing 0.2% Triton × 100
and 1% normal goat serum overnight at 4°C. Dilutions of
antibodies were as follows: anti-GFAP (1:1500, Sigma);
anti-Iba-1 (1:1000, WAKO) (additional file 2). Develop-
ment was conducted by the ABC method (Pierce, Rock-
ford, IL), and immunoreactivity was visualized by 3,3-
diaminobenzidine oxidation as chromogen, with or without
nickel enhancement. Images were acquired with Zeiss
Axiocam high resolution digital color camera, using the
same settings and the segmentation parameters (MCID
software, InterFocus Imaging, UK) were constant for a
given marker and experiment. The mean value for each
animal per region results from the analysis of 5-6 sections.
Ab levels
Ab measurements were performed by two ELISA kits, one
for each fragment (Ab1-40 and Ab1-42), from Biosource
following the manufacturer instructions. The samples
were sonicated (5 sec) in 10 vol of protein lysis buffer con-
taining protease inhibitors (see Western blotting for
details). The lysate was centrifuged (18,000 × g, for 10 min
at 4°C). The supernatant was considered soluble and the
pellets were further extracted by sonicating with formic
acid and centrifuged. Prior to the Elisa the unsoluble sam-
ples were diluted 3 times with Tris 1 M, pH 10, while the
soluble samples were diluted 5 times in Elisa buffer. The
results were expressed as pg/mg of protein measured by
the Bradford method, using BSA as standard.
Ab transport
A double-chamber choroid plexus epithelial cell culture
system mimicking the blood-cerebrospinal fluid (CSF)
interface was used for in vitro studies, as previously
described [59]. After seeding, the cells were incubated
for 24 h and thereafter Ab1-40 (5 μg/ml) was added to
the lower chamber in the absence or presence of the
cannabinoid agonists (500 nM). At different time points
the medium was collected from the upper chamber, and
the Ab1-40 content was determined by immunoblotting.
In other experiments Ab1-40 levels were assessed by
selective Elisa kits (Biosource) as described above.
Western blotting
Western blot was performed as described previously [61].
In brief, tissues were sonicated in lysis buffer, samples
were centrifuged at high speed for 10 min, and superna-
tants were collected. Total protein was assessed by the
Bio-Rad (Hercules, CA) protein assay. An aliquot of each
sample (40 μg of protein) was separated by SDS-PAGE
(10%), and proteins were transferred from the gels onto
nitrocellulose membranes. The blots were blocked with
1% defatted dry milk for 1 h at room temperature and
incubated overnight at 4°C with the following antibodies:
anti-GFAP (1:10.000, DAKO), anti-CB2 (1:10.000, Affinity
Bioreagents); anti-COX2 (1:100, Abcam); anti-p-GSK3b
(1:5000, BD); anti-GSK3b (1:1.500, Cell Signaling) (addi-
tional file 2). Finally, samples were subjected to enhanced
chemiluminescence and densitometric analysis. Band den-
sitometric analysis was performed by Quantity One quan-
titation software (version 5.0; Bio-Rad) from film
exposures; the background was subtracted, and the optical
density percentage was obtained considering 100% the
control samples within the same film. Tubulin was used as
loading control. Every membrane contained samples from
each treatment group, for comparison purposes.
The specificity of the CB2 antibodies used (additional file
2) was assessed by preincubating with the human anti-
genic peptide (2 μ/ml overnight at 4°C under agitation), as
stated in additional file 2, before its use in Western blot-
ting, which resulted in blockade of the immunoreactive
signal (see additional file 3).
Analysis of mRNA levels by quantitative real-time PCR
Total RNA from cortex was extracted using TRIzol
reagent according to the manufacturer’s instructions (Invi-
trogen). To avoid interference with potential genomic
DNA amplification, we treated 1 μg of total RNA with 1 μl
DNAse I (Invitrogen) plus 1 μl of 10× Buffer (Invitrogen).
The samples were incubated at RT for 15 min. EDTA (25
mM) was added to the mixture and the samples were
incubated at 65°C for 15 min to heat inactivate the DNAse
I. For cDNA synthesis a total of 1 μg of RNA from the dif-
ferent samples were reverse-transcribed for 75 min at 42°
C using 5 U of avian myeloblastosis virus reverse tran-
scriptase (Promega) in the presence of 20 U of RNasin
(Promega). The real-time PCR reaction was performed in
25 μl using the fluorescent dye SYBR Green Master mix
(Applied Biosystems) and a mixture of 5 pmol of reverse
and forward primers. The primers used were for TNF-a
forward primer 5’ CATCTTCTCAAAATTCGAGTGA-
CAA 3’ and reverse primer 5’ TGGGAGTAGACAAGG-
TACAACCC 3’ and for IL-6 forward primer 5’ GAGGA
TACCACTCCCAACAGACC 3’ and reverse primer 5’
AAGTGCATCATCGTTGTTCATACA 3’. Quantification
was performed on an ABI PRISM 7900 sequence detection
Martín-Moreno et al. Journal of Neuroinflammation 2012, 9:8
http://www.jneuroinflammation.com/content/9/1/8
Page 12 of 15
system (Applied Biosystems). PCR cycles proceeded as fol-
lows: initial denaturation for 10 min at 95°C, then 40
cycles of denaturation (15 sec, 95°C), annealing (30 sec,
60°C), and extension (30 sec, 60°C). The melting-curve
analysis showed the specificity of the amplifications.
Threshold cycle, which inversely correlates with the target
mRNA level, was measured as the cycle number at which
the reporter fluorescent emission appears above the back-
ground threshold (data not shown). Data analysis is based
on the ΔCT method with normalization of raw data to a
house-keeping gene (b-actin). All of the PCRs were per-
formed in triplicate.
Statistical analysis
Statistical significance analysis was assessed by using
one-way or two-way analysis of variance (ANOVA) fol-
lowed by unpaired Student’s t test (version 5.0, Prism
software, GraphPad, USA). A value of p < 0.05 was con-
sidered significant.
Additional material
Additional file 1: Co-localization of CB2 and Iba-1 inmmunostaining
in quinolinic acid injected striatum. Iba-1 positive microglia in striatum
also express CB2 receptor protein ipsilateral to the toxin injection, but
was absent in the contralateral (unlesioned) striatum. Tg APP microglial
cells are devoid of CB2 immunostaining.
Additional file 2: Additional methods. (quinolinic acid striatal lesion
and blockade of CB2 antibodies with CB2 blocking peptide) and
additional file 1, which includes the antibodies, commercial source and
dilution, used in immunohistochemistry and Western blotting.
Additional file 3: Blockade of CB2 antibodies 744 and 746 with CB2
antigenic peptide. The CB2 peptide completely blocked
immunostaining.
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